Pharmaxis shares dive after US review Updated: 11:53, Thursday January 31, 2013 Shares in pharmaceutical company Pharmaxis have dived by more than 40 per cent after its cystic fibrosis treatment received a negative review from advisers to regulators in the United States.
Pharmaxis shares dive after US review